GoodRx/$GDRX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About GoodRx
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
- Ticker
- $GDRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 697
- Headquarters
- Santa Monica, United States
- Website
- www.goodrx.com
GoodRx Metrics
BasicAdvanced
$1.2B
73.53
$0.05
1.60
-
Price and volume
Market cap
$1.2B
Beta
1.6
52-week high
$3.89
52-week low
$1.77
Average daily volume
1M
Financial strength
Current ratio
1.381
Quick ratio
0.423
Long term debt to equity
0.816
Total debt to equity
0.832
Interest coverage (TTM)
2.19%
Profitability
EBITDA (TTM)
108.776
Gross margin (TTM)
90.83%
Net profit margin (TTM)
2.07%
Operating margin (TTM)
11.36%
Effective tax rate (TTM)
60.75%
Revenue per employee (TTM)
$1,130,000
Management effectiveness
Return on assets (TTM)
3.05%
Return on equity (TTM)
2.52%
Valuation
Price to earnings (TTM)
73.526
Price to revenue (TTM)
1.521
Price to book
1.83
Price to tangible book (TTM)
63.42
Price to free cash flow (TTM)
9.072
Free cash flow yield (TTM)
11.02%
Free cash flow per share (TTM)
0.385
Growth
Revenue change (TTM)
-1.83%
Earnings per share change (TTM)
-46.78%
3-year revenue growth (CAGR)
1.76%
3-year earnings per share growth (CAGR)
32.84%
What the Analysts think about GoodRx
Analyst ratings (Buy, Hold, Sell) for GoodRx stock.
Analyst projections of the future price of GoodRx stock.
Bulls say / Bears say
Pharma Direct is scaling quickly: revenue rose 76% year on year in the second quarter, and GoodRx raised its full-year revenue and adjusted EBITDA guidance. This could help the company return to growth sooner than previously expected. (GoodRx)
GoodRx is positioned to benefit from the shift towards direct-to-consumer medicine pricing: the company says it is a key integration partner for manufacturers participating in TrumpRx. If this channel expands demand rather than displacing existing transactions, it could create another route for GoodRx to reach consumers. (SEC)
The legacy prescription-transactions business is shrinking sharply: second-quarter revenue fell 26% year on year, with fewer monthly active consumers and lower unit economics among the pressures. This remains the largest revenue stream, so continued declines could outweigh growth elsewhere. (GoodRx)
Profitability weakened even as the business shifted towards faster-growing products: second-quarter net income fell to $8.5 million from $12.8 million, while adjusted EBITDA declined to $63.7 million from $69.4 million. The first-half results also showed lower net income and adjusted EBITDA than a year earlier. (SEC)
GoodRx still faces uncertainty over its consumer-privacy class action: the court has denied preliminary approval of proposed settlements, and another approval motion was pending in the latest filing. The company had accrued $30.5 million for settlement and indemnification costs, but warned that the eventual loss could differ from its estimate. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2026.
GoodRx Financial Performance
Revenues and expenses
GoodRx Earnings Performance
Company profitability
Upcoming events
No upcoming events
GoodRx News
AllArticlesVideos
Funds containing GoodRx
Fund name | Fund size | $GDRX weighting |
|---|---|---|
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.01% |
SPDR MSCI All Country World IM€SPYI | $7.7B | 0.00% |
iShares MSCI World Small Cap$WSML | $9B | 0.00% |
iShares MSCI World Small Cap€IUSN | $9B | 0.00% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.